IPO registrations (S-1, F-1) · Registrants
NRX Pharmaceuticals, Inc.
- SEC CIK
- 1719406 · filings on EDGAR ↗
- Former names
- Big Rock Partners Acquisition Corp. (2017–2021)
- Registration
- Form S-1, first filed 2017-10-13, last 2024-11-14; 5 initial registrations, 4 amendments
- Outcome
- Final prospectus filed 2017-11-21; declared effective 2017-11-20; withdrawal requested 2025-06-24
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1201 ORANGE STREET, SUITE 600, Wilmington, DE 19801
- EIN
- 82-2844431
- Ticker
- NRXP (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- NRX Pharmaceuticals, Inc. on the corporate pages
Offering terms
- Final price
- $10.00 per share (424B4 filed 2017-11-21, an initial public offering)
- Shares sold
- 6,000,000
- Gross proceeds
- $60,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol BRPA
- Lead underwriters
- I-Bankers Securities (600,000 shares)
- Syndicate
- Units EarlyBirdCapital, Inc (5,400,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: BIG ROCK PARTNERS ACQUISITION CORP. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: NRX PHARMACEUTICALS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Form D issuer: NRX Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- Lobbying client: NRX PHARMACEUTICALS Fuzzy (name and state)
- Lobbying client: NRX PHARMACEUTICALS Fuzzy (name and state)
- SEC filer: Big Rock Partners Acquisition Corp. EXACT (CIK (EXACT))
- Person page: Albert G Rex Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Troy T Taylor Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 22
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2017-10-13 | S-1 | S-1 (registration) | Big Rock Partners Acquisition Corp. | 0001654954-17-009431 ↗ |
| 2017-11-14 | S-1/A | S-1/A (amendment) | Big Rock Partners Acquisition Corp. | 0001654954-17-010676 ↗ |
| 2017-11-17 | S-1/A | S-1/A (amendment) | Big Rock Partners Acquisition Corp. | 0001654954-17-010852 ↗ |
| 2017-11-20 | S-1/A | S-1/A (amendment) | Big Rock Partners Acquisition Corp. | 0001654954-17-010894 ↗ |
| 2017-11-20 | S-1MEF | S-1MEF (added securities) | Big Rock Partners Acquisition Corp. | 0001654954-17-010897 ↗ |
| 2017-11-20 | EFFECT | EFFECT (declared effective) | Big Rock Partners Acquisition Corp. | 9999999995-17-003025 ↗ |
| 2017-11-21 | 424B4 | 424B4 (final prospectus) | Big Rock Partners Acquisition Corp. | 0001654954-17-010931 ↗ |
| 2021-05-21 | EFFECT | EFFECT (declared effective) | Big Rock Partners Acquisition Corp. | 9999999995-21-002054 ↗ |
| 2021-06-25 | S-1 | S-1 (registration) | NRX Pharmaceuticals, Inc. | 0001193125-21-200558 ↗ |
| 2021-07-06 | S-1/A | S-1/A (amendment) | NRX Pharmaceuticals, Inc. | 0001193125-21-208673 ↗ |
| 2021-07-09 | EFFECT | EFFECT (declared effective) | NRX Pharmaceuticals, Inc. | 9999999995-21-002705 ↗ |
| 2021-09-03 | S-1 | S-1 (registration) | NRX Pharmaceuticals, Inc. | 0001104659-21-113002 ↗ |
| 2021-09-15 | EFFECT | EFFECT (declared effective) | NRX Pharmaceuticals, Inc. | 9999999995-21-003551 ↗ |
| 2022-04-08 | S-1 | S-1 (registration) | NRX Pharmaceuticals, Inc. | 0001104659-22-044187 ↗ |
| 2022-04-19 | EFFECT | EFFECT (declared effective) | NRX Pharmaceuticals, Inc. | 9999999995-22-001031 ↗ |
| 2022-05-03 | EFFECT | EFFECT (declared effective) | NRX Pharmaceuticals, Inc. | 9999999995-22-001274 ↗ |
| 2022-05-03 | EFFECT | EFFECT (declared effective) | NRX Pharmaceuticals, Inc. | 9999999995-22-001282 ↗ |
| 2022-06-10 | EFFECT | EFFECT (declared effective) | NRX Pharmaceuticals, Inc. | 9999999995-22-001758 ↗ |
| 2022-06-21 | EFFECT | EFFECT (declared effective) | NRX Pharmaceuticals, Inc. | 9999999995-22-001833 ↗ |
| 2024-11-14 | S-1 | S-1 (registration) | NRX Pharmaceuticals, Inc. | 0001437749-24-035167 ↗ |
| 2025-06-24 | RW | RW (withdrawal request) | NRX Pharmaceuticals, Inc. | 0001437749-25-021178 ↗ |
| 2025-12-22 | EFFECT | EFFECT (declared effective) | NRX Pharmaceuticals, Inc. | 9999999995-25-003879 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-11-20 | S-1/A | registration statement | $25.00 | - | - | 0 | primary document; price sentence | document ↗ | ||
| 2017-11-21 | 424B4 | final prospectus | $10.00 | 6,000,000 | $60,000,000 | Nasdaq BRPA | 2 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ACKERMAN RICHARD | Director,Officer; Director,Officer,TenPercentOwner | President and CEO; President & CEO | 4 | 2017–2021 | |
| Big Rock Partners Sponsor, LLC | Director,Officer; TenPercentOwner | President and CEO | 4 | 2017–2021 | |
| BIRDOFF RICHARD | Director | 1 | 2017 | ||
| FONG MICHAEL | Director | 1 | 2017 | ||
| KIM BENNETT | Officer | Chief Invt. Ofc. & Corp. Sec. | 1 | 2017 | |
| Koenig Stuart F. | Director | 1 | 2017 | ||
| REX ALBERT G. | Director | 1 | 2017 | person page Fuzzy | |
| Taylor Troy T | Director | 1 | 2017 | person page Fuzzy | |
| Wittman Lori | Director,Officer | CFO | 1 | 2017 | |
| BRAC Lending Group LLC | TenPercentOwner | 3 | 2018–2021 | ||
| Levine Steven | TenPercentOwner | 1 | 2018 | ||
| NUSSBAUM DAVID M | TenPercentOwner | 1 | 2018 | ||
| Polar Asset Management Partners Inc. | TenPercentOwner | 2 | 2020 | ||
| Besthof Robert | Officer | Chief Comm. & Patient Officer; Interim CEO | 4 | 2021–2022 | |
| Daigneault Alessandra | Officer | General Counsel & Secretary | 3 | 2021 | |
| Flynn Patrick John | Director | 5 | 2021–2025 | ||
| Fricker William | Officer | CFO & Treasurer | 2 | 2021 | |
| Glied Sharon | Director | 3 | 2021–2022 | ||
| Gorovitz Aaron | Director | 4 | 2021–2023 | ||
| Hurvitz Chaim | Director | 6 | 2021–2025 | ||
| Javitt Daniel C. | TenPercentOwner | 9 | 2021–2022 | ||
| Javitt Jonathan C | Director,Officer,TenPercentOwner; Director,TenPercentOwner | Chairman and Chief Scientist; Chief Executive Officer; Chief Scientist | 10 | 2021–2025 | |
| Troy Daniel | Director | 2 | 2021 | ||
| McMaster Herbert Raymond | Director | 2 | 2021 | ||
| Strassberg Ira S | Officer | Chief Financial Officer | 1 | 2022 | |
| VAN VOORHEES SETH | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 4 | 2022 | |
| Willard Stephen H | Director,Officer | Chief Executive Officer; CHIEF EXECUTIVE OFFICER | 2 | 2022 | |
| Narido Richard Clavano | Officer | Interim CFO | 1 | 2023 | |
| Rehnquist Janet | Director | 1 | 2024 | ||
| McBride Dennis | Director | 2 | 2024–2025 | ||
| ABRAMS MICHAEL S | Officer | Chief Financial Officer | 2 | 2024–2025 | |
| B Group, Inc. | TenPercentOwner | 1 | 2025 | ||
| Casper Joseph Michael | Officer | Chief Operating Officer | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-03-07 | NRX Pharmaceuticals, Inc. | Biotechnology | $3,500,000 | $3,500,000 | 2 | 1 |
| 2017-11-22 | Big Rock Partners Acquisition Corp. | Commercial | $2,750,000 | $2,525,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | BIG ROCK PARTNERS ACQUISITION CORP. | FL | State business registries | EIN (EXACT, as the state registration reports it) |
| Business registration | NRX PHARMACEUTICALS, INC. | FL | State business registries | EIN (EXACT, as the state registration reports it) |
| Contractor | FIVE JARS | DE | Nonprofit contractors (Form 990) | same street address and ZIP code, 1201 ORANGE ST STE 600 19801 (FUZZY: a shared address, not proof of a shared organization) |
| Form D issuer | NRX Pharmaceuticals, Inc. | DE | Form D private offerings | CIK (EXACT) |
| Lobbying client | NRX PHARMACEUTICALS | DE | Federal lobbying (LDA) | name and state |
| Lobbying client | NRX PHARMACEUTICALS | DE | Federal lobbying (LDA) | name and state |
| SEC filer | NRX Pharmaceuticals, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | NRx Pharmaceuticals | DE | Trademarks (USPTO) | name and state |
| Person page | Albert G Rex | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Troy T Taylor | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, DE first:
- Merus N.V. DE
- Prelude Therapeutics Inc DE
- Applied Molecular Transport Inc. DE
- Lomond Therapeutics Holdings, Inc. DE
- NovaCardia Inc CA
- MyoKardia, Inc. CA
- Bioquest Corp CA
- Regen BioPharma Inc CA
- Catalent, Inc. NJ
- Korro Bio, Inc. MA
In other datasets, the same topic (Health) in DE:
- Nonprofit: 1212 CORPORATION (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health